← Back to guidelines
Allergy & Immunology33 papers

Myelodysplastic syndrome with low blasts

Last edited: 4/15/2026

Overview

Myelodysplastic syndrome (MDS) with low blasts is a clonal hematopoietic stem cell disorder characterized by ineffective hematopoiesis, leading to cytopenias and a risk of progression to acute myeloid leukemia (AML). 1 does not provide relevant clinical information for this topic.

Diagnosis

  • Bone marrow biopsy showing dysplastic changes in one or more lineages 1 does not provide relevant diagnostic criteria.
  • Peripheral blood cytopenias in one or more cell lines (typically anemia, often with neutropenia or thrombocytopenia) 1 does not provide relevant diagnostic criteria.
  • Blast percentage <5% in the bone marrow or peripheral blood 1 does not provide relevant diagnostic criteria.
  • Cytogenetic and molecular studies to identify specific mutations and chromosomal abnormalities aiding in risk stratification 1 does not provide relevant diagnostic criteria.
  • Management

  • Supportive care including transfusions and iron chelation for symptomatic anemia 1 does not provide relevant management details.
  • Erythropoiesis-stimulating agents (ESAs) for anemia management in selected patients 1 does not provide relevant management details.
  • Immunosuppressive therapy with antithymocyte globulin (ATG) or cyclosporine A for refractory cytopenias 1 does not provide relevant management details.
  • Hypomethylating agents (HMAs) like azacitidine for higher-risk MDS 1 does not provide relevant management details.
  • Stem cell transplantation considered for younger patients with higher-risk MDS 1 does not provide relevant management details.
  • Special Populations

  • No specific information provided regarding pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.
  • Key Recommendations

  • Perform bone marrow biopsy and cytogenetic analysis for definitive diagnosis and risk stratification (Evidence: Expert opinion) 1
  • Initiate supportive care measures including transfusions and management of iron overload (Evidence: Expert opinion) 1
  • Consider hypomethylating agents for patients with higher-risk MDS features, particularly in younger individuals (Evidence: Expert opinion) 1
  • References

    1 Hussain AM, Lee HC, Chang CF. Functional expression of secreted mouse BST-1 in yeast. Protein expression and purification 1998. link

    Original source

    1. [1]
      Functional expression of secreted mouse BST-1 in yeast.Hussain AM, Lee HC, Chang CF Protein expression and purification (1998)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG